Role of CBC as a Prognostic Marker for DKA Patients

Status Not yet recruiting

Clinical Trial Summary

1. To evaluate that change of platelet-to-lymphocyte Ratio affect the duration of hospital stay and mortality rate of DKA patients 2. To assess the impact of red blood cell distribution width (RDW) on the prognosis of diabetic ketoacidosis patients 3. To evaluate the changes in hematological parameters (RBCs,Hct,Hb,MCV,PLT,WBCs) and their correlations with acidosis level and dehydration during ketoacidosis treatment

Clinical Trial Description

Diabetes Mellitus (DM) is a serious threat to global health with an increasing prevalence and incidence rates,The number of people who had DM was 463 million in 2019,and according to international diabetes federation [IDF] this number will have reached 700 million in 2045 (1). One of the most serious complication of DM is diabetic ketoacidosis (DKA) which is a life-threatening acute copmlication of diabetes mellitus [DM], [DKA] occur in patients with both type 1 and type 2 diabetes, for which type 1 and type 2 diabetes is responsible for 66% and 34% patients respectively (2,3). Despite the development of improved treatment, DKA remains at a high incidence of recurrence and a leading cause of mortality among patients with DM, resulting in an elevated burden for patients,hospitals,and healthcare providers(4,5). As a systemic metabolic disease,DKA has been reported to be associated with the inflammatory response of the hyperglycaemic state(6,7). the inflammatory markers like (platelets-lymphocyte ratio, red blood cell distribution width) play an important role in the development of inflammation and affect prognosis of DKA One of the most things that affected by diabetic ketoacidosis is hydration status, As DKA can cause dehydration and some complications may result from that such as cerebral edema,coma or even death(8,9). there are many methods to estimate the hydration status such as clinical dehydration scale(CDS), hematological parameters (RBC, Hct , Hb MCV, PLT ,WBC) which are used as an alternative approach to estimate the extent of dehydration in DKA patients(10,11). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05666895
Study type	Observational
Source	Assiut University
Contact	Mohamed Mamdouh Tawfik abdelaleem
Phone	01060264431
Email	mohamaad81095@gmail.com
Status	Not yet recruiting
Phase
Start date	January 1, 2023
Completion date	July 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05649891` - Checklists Resuscitation Emergency Department	N/A
Completed	`NCT03660189` - Two Bag System for Diabetic Ketoacidosis	N/A
Terminated	`NCT03066440` - Double Blinded Randomized Control Trial of Types of IVF in Children With DKA	Phase 4
Completed	`NCT04940897` - Use of Blood Ketone Meters to Improve Ambulance Hyperglycaemia Care	N/A
Completed	`NCT02930044` - Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis	N/A
Completed	`NCT04926740` - Intravenous Fluids in Adults With Diabetic Ketoacidosis in the Emergency Department	N/A
Terminated	`NCT04567225` - Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management	Phase 4
Completed	`NCT04017221` - Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes
Recruiting	`NCT03717896` - Thiamine as Adjunctive Therapy for Diabetic Ketoacidosis	Phase 2
Terminated	`NCT02548494` - Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes	N/A
Completed	`NCT02006342` - Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis	N/A
Completed	`NCT01753921` - Evaluation of a Non-invasive Brain Compliance Measurement Device
Completed	`NCT01365793` - Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis	Phase 3
Completed	`NCT00426413` - Ketosis Prone Diabetes in African-Americans	N/A
Not yet recruiting	`NCT05867797` - Risk Factors and Outcomes of Acute Kidney Injury in Patients With Diabetic Ketoacidosis at Sohag University Hospital.
Terminated	`NCT04234867` - Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)	Phase 1
Not yet recruiting	`NCT05752279` - Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis	Phase 3
Completed	`NCT04825639` - Identifying Risk Factors for Developing AKI in Sepsis
Recruiting	`NCT05155917` - Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care	Phase 2
Recruiting	`NCT05383404` - Clinical and Laboratory Parameters Associated With Different Degrees of Dehydration Among Children With Diabetic Ketoacidosis

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.